Contract development and manufacturing organization

Since 2006, David has been pivotal to Northstar, leading its Eastern European Office in Prague and holding major shares. With two decades in the Eastern Europe and CIS financial sectors, his knowledge is unmatched. He's held key roles at notable Eastern European firms, including CFO at Corbina Telecom and Kazintel, and CEO at Direct Net in Prague and Credit Suisse Asset Management Czech Republic. He boasts an MBA from the Czech Management Center, MA from Boston University, and a BA from Washington University. His expertise covers management, M&A, and business growth, making him a significant figure in finance.

He Graduated from St. Gallen Management School in Switzerland in Economics and Marketing. Major Shareholder of Northstar since 2008, Head of European Office in Stuttgart. For more than 20 years acted as a trusted advisor to the boards and owners of various mid cap companies and has long standing local experience in Eastern Europe. Before joining NorthStar, Hans was a co-founder of DTB Financial Services GmbH, an investment banking firm focused on Eastern Europe and a Director of Funk Group GmbH, the leading German insurance broker and risk management firm.

Rainer, who's now 46, began his journey with Bayer in Germany before diving into pharmaceutical consulting in the early 2000s. Having spent over a quarter-century in the field, Rainer has a knack for shaping GMP production systems, amplifying them using QbD and PAT techniques, and leading the charge in digitizing pharmaceutical business workflows. These days, he's at the helm of both J&K Group GmbH and the European Cannabis Association, and he's also the Vice Chairman of Green Mobility Future. Rainer's vast and varied know-how places him at the forefront of the industry, seamlessly merging innovation with top-notch quality.

He graduated from the University of Chemistry and Technology in organic chemistry and completed his Ph.D.  at the Czech Academy of Sciences. His fascination with chemical processes has always pushed him one step further. He is co-founder of the pharmaceutical company CB21 Pharma Ltd. and the associated brand CANNEFF®. In CB21 R&D he is responsible mainly for pharmaceutical development.